Navigation Links
Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease
Date:8/12/2009

BROOMFIELD, Colo., Aug. 12 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, announced today publication of a scientific paper in the peer-reviewed journal Nutrition & Metabolism. The paper, entitled "Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial" suggests that daily administration of AC-1202 (Axona(TM)) can help improve cognition and memory in patients with mild-to-moderate Alzheimer's disease (AD).

"Accera has taken a novel approach to Alzheimer's therapy with the development of Axona," said Samuel Henderson, Ph.D., executive director of research at Accera and lead author of the paper. "Publication of our findings confirms our earlier pre-clinical and clinical findings which show that using ketone bodies can be an effective and safe method to approach this devastating disease."

Alzheimer's disease is characterized by early and region-specific declines in the brain's ability to metabolize glucose, its main fuel source. Prior clinical evidence suggests that ketones can serve as an alternative energy source for the brain during glucose deprivation. Axona, which was launched as a prescription medical food product in the US in March 2009, is a proprietary formulation of a pharmaceutical-grade medium chain triglyceride (AC-1202) designed to safely elevate serum ketone bodies, thus providing an alternative energy source for the brain. In this Phase IIb trial, AC-1202 was used to determine whether chronic induction of mild ketosis in patients with probable Alzheimer's disease could improve cognition and short term memory performance.

The 90-day, randomized, double-blind, placebo-controlled, parallel-group study, evaluated the effect of daily dosing of AC-1202 in patients diagn
'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
2. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
3. Accera, Inc. Completes $35 Million Series C Financing
4. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
5. Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimers Disease
6. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
7. Accera, Inc. to Present at Upcoming Investor Conferences
8. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
9. Accera, Inc. to Support the Alzheimers Foundation of Americas National Memory Screening Day Through On-line Awareness Effort
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Select Medical Corporation ... Federal Trade Commission granted early termination of the ... Act of 1976, as amended, applicable to the ... Corporation, a joint venture that Select has created ... As previously announced, MJ Acquisition Corporation has ...
(Date:5/20/2015)... NEW YORK , May 20, 2015 /PRNewswire-USNewswire/ ... announced a leadership gift of $100 million from ... help create a new laboratory building that will ... campus extension. The Marie-Josée and Henry R. Kravis ... over the FDR Drive, spanning approximately three city ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
(Date:5/20/2015)... DENVER , May 20, 2015 /PRNewswire/ ... today announced that it is an official ... Management Executives (CHIME) Cooperative Members Services Program. ... of compliant, managed cloud services and best ... of healthcare CIOs and service providers, enabling ...
Breaking Biology Technology:Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... Jim Doyle on Thursday announced that three Wisconsin businesses ... Department of Commerce Technology Assistance Grant (TAG) and Technology ... follows: , , Functional Biosciences, Inc. , ... DNA sequencing. It will receive a $250,000 TVF loan ...
... week that he is planning to have a radio ... provide access to his electronic medical records. Meanwhile ... announced that it has licensed California research firm Chemicon ... On another note, Madison biotech firm Platypus Technologies announced ...
... Inc. , a Madison-based manufacturer of high-power diode lasers ... $1.4 million in funding for Phase II of the ... Defense Advanced Research Projects Agency. , ,The ... laser's power conversion efficiency -- to lower the ambient ...
Cached Biology Technology:Alfalight garners $1.4 million defense funding for diode program 2
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2
... (Santa Barbara, Calif.) An international team of researchers ... that happens in virtually every cell of our bodies. ... folded chains of amino acids assume their specific shapes, ... widely: In the human body, proteins fold to become ...
... family history of liver cancer is reported to increase risk ... findings published in the May issue of Hepatology , ... Liver Diseases. The study also shows 70-fold elevated risk of ... markers for hepatitis B (HBV) or hepatitis C (HCV). ...
... Princeton University researchers have observed a self-degradation response to ... provide new answers to lingering questions among scientists about ... that depression is not solely linked to the neurotransmitter ... PLoS ONE , researchers based in the lab of ...
Cached Biology News:In protein folding, internal friction may play a more significant role than previously thought 2Family history of liver cancer increases risk of developing the disease 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 3Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 4